Skip to main
IVVD

Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd Inc (IVVD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Invivyd is showing strong potential as a biopharmaceutical company, with a proven track record in producing effective anti-SARS-CoV-2 antibodies, such as PEMGARDA, and a highly differentiated and potent next-generation antibody, VYD2311, in development. With a potential market availability in 2027, early feedback from stakeholders has been favorable, and reimbursement pushback has been minimal for existing products, indicating strong market potential. Additionally, the company's focus on single-dose administration and a flexible multidose option for higher-risk periods may improve commercial viability and accessibility. Overall, Invivyd is well-positioned to drive success in multiple infectious disease targets, and investors may be underestimating the potential of its products.

Bears say

Invivyd is currently conducting clinical trials for its lead product PEMGARDA, with potential commercialization in 2027. However, the success of this product and subsequent BLA submission depends heavily on the results of the DECLARATION and LIBERTY trials, with potential risks including unexpected outcomes and regulatory uncertainty. Additionally, the company faces risks in the increasingly complex and price-sensitive commercial market for biopharmaceuticals.

Invivyd Inc (IVVD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Invivyd Inc (IVVD) Forecast

Analysts have given Invivyd Inc (IVVD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Invivyd Inc (IVVD) has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Invivyd Inc (IVVD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.